Literature DB >> 26806183

Efficacy and safety of hyaluronic acid in the management of osteoarthritis: Evidence from real-life setting trials and surveys.

Emmanuel Maheu1, François Rannou2, Jean-Yves Reginster3.   

Abstract

The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm recommends intra-articular (IA) hyaluronic acid (HA) for management of knee osteoarthritis (OA) as second-line treatment in patients who remain symptomatic despite use of non-steroidal anti-inflammatory drugs (NSAIDs). This recommendation is based upon accumulating evidence that IA HA provides a significant benefit in knee OA. There is good evidence that IA HA injections reduce pain and increase function in knee OA, and the benefits are long-lasting as compared with IA corticosteroids. Evidence from real-life studies of repeat courses of IA HA demonstrates an improvement in pain or function lasting up to 40 months (12 months after the last injection cycle), a reduction in use of concomitant analgesia by up to 50%, and suggests that there may be a delay in the need for total knee replacement (TKR) of around 2 years. The clinical benefit of IA HA on knee OA may be 2-fold: (i) mechanical viscosupplementation of the joint (allowing lubrication and shock absorption) and (ii) the re-establishment of joint homeostasis through induction of endogenous HA production, which continues long after the exogenous injection has left the joint. The magnitude of the clinical effect may be different for different HA products, but this has not been proven so far and requires further investigation. IA HA injections are generally considered to be safe, although a slightly higher number of cases of local reactions and post-injection non-septic arthritis has been reported with high molecular weight cross-linked HAs. The use of IA HA in knee OA patients with mild-moderate disease, and for more severe patients wishing to delay TKR surgery, is recommended by the ESCEO task force. Further investigation into the OA patient types most likely to benefit from IA HA is warranted. Viscosupplementation with IA HA is a safe and effective component of the multi-modal management of knee OA.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hyaluronic acid; Intra-articular injection; Knee osteoarthritis

Mesh:

Substances:

Year:  2015        PMID: 26806183     DOI: 10.1016/j.semarthrit.2015.11.008

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  60 in total

Review 1.  Real-world evidence in rheumatic diseases: relevance and lessons learnt.

Authors:  Durga Prasanna Misra; Vikas Agarwal
Journal:  Rheumatol Int       Date:  2019-02-06       Impact factor: 2.631

Review 2.  Type 2 diabetes mellitus and osteoarthritis.

Authors:  Nicola Veronese; Cyrus Cooper; Jean-Yves Reginster; Marc Hochberg; Jaime Branco; Olivier Bruyère; Roland Chapurlat; Nasser Al-Daghri; Elaine Dennison; Gabriel Herrero-Beaumont; Jean-François Kaux; Emmanuel Maheu; René Rizzoli; Roland Roth; Lucio C Rovati; Daniel Uebelhart; Mila Vlaskovska; André Scheen
Journal:  Semin Arthritis Rheum       Date:  2019-01-11       Impact factor: 5.532

3.  Towards reaching consensus on hyaluronic acid efficacy in knee osteoarthritis.

Authors:  Larry E Miller
Journal:  Clin Rheumatol       Date:  2019-05-17       Impact factor: 2.980

4.  Decision Algorithms for the Retreatment with Viscosupplementation in Patients Suffering from Knee Osteoarthritis: Recommendations from the EUROpean VIScosupplementation COnsensus Group (EUROVISCO).

Authors:  Raghu Raman; Yves Henrotin; Xavier Chevalier; Alberto Migliore; Jörg Jerosch; Jordi Montfort; Hervé Bard; Dominique Baron; Pascal Richette; Thierry Conrozier
Journal:  Cartilage       Date:  2017-02-01       Impact factor: 4.634

5.  Is Intra-Articular Injection of Synvisc Associated with a Delay to Knee Arthroplasty in Patients with Knee Osteoarthritis?

Authors:  Kevin L Ong; Maria Runa; Edmund Lau; Roy Altman
Journal:  Cartilage       Date:  2018-05-21       Impact factor: 4.634

6.  Clinical therapy of hyaluronic acid combined with platelet-rich plasma for the treatment of knee osteoarthritis.

Authors:  Wenxing Yu; Peng Xu; Guiling Huang; Lin Liu
Journal:  Exp Ther Med       Date:  2018-07-06       Impact factor: 2.447

7.  Effects of Viscosupplementation on Quality of Knee Joint Arthrokinematic Motion Analyzed by Vibroarthrography.

Authors:  Dawid Bączkowicz; Grzegorz Skiba; Mirosław Szmajda; Ivan Vařeka; Krzysztof Falkowski; Kevin Laudner
Journal:  Cartilage       Date:  2019-05-09       Impact factor: 4.634

Review 8.  Hyaluronic acid vs corticosteroids in symptomatic knee osteoarthritis: a mini-review of the literature.

Authors:  Salvatore Bisicchia; Cosimo Tudisco
Journal:  Clin Cases Miner Bone Metab       Date:  2017-10-25

Review 9.  The protective role of glutathione in osteoarthritis.

Authors:  Thiago Setti; Miguel Gustavo Luz Arab; Gabriel Silva Santos; Natasha Alkass; Marco Antonio Percope Andrade; José Fábio Santos Duarte Lana
Journal:  J Clin Orthop Trauma       Date:  2020-09-09

10.  A Malaysian Delphi consensus on managing knee osteoarthritis.

Authors:  Swan Sim Yeap; Syamsul Rizal Abu Amin; Hazlyna Baharuddin; Kar Chai Koh; Joon Kiong Lee; Verna Kar Mun Lee; Nor Hamdan Mohamad Yahaya; Cheh Chin Tai; Maw Pin Tan
Journal:  BMC Musculoskelet Disord       Date:  2021-06-04       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.